Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748691 | 0.93 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL31748584 | 0.84 | GABRA5 (0.33) | DGAT1GABRA5TNKSPARP1TNKS2 | |
| SCHEMBL31748473 | 0.79 | — | — | |
| SCHEMBL31748697 | 0.78 | GABRA5 (0.34) | DGAT1GABRA5TNKSPARP1TNKS2 | |
| SCHEMBL31748550 | 0.77 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL31748345 | 0.75 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL31748465 | 0.74 | TNKS (0.35) | GABRA5TNKSPARP1TNKS2 | |
| SCHEMBL31748640 | 0.71 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31748554 | 0.68 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL31748662 | 0.66 | DGAT1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | DGAT1 3043/4885GABRA5 3222/4885TNKS 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.